Xuchu Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuchu Hu has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Huaiqiu Huang
Department of Dermatology and Venereology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
11 shared publications Xinbing Yu
Sun Yat-sen University
7 shared publicationsWenjia Gan
Department of Clinical Laboratory, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
6 shared publicationsJiajia Chen
Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
4 shared publications- Lilin Huang
Department of Pediatrics, Guangdong Women and Children Hospital, Guangzhou, China
4 shared publications Zhaoping Zhang
Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
4 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (9) , 706
SgtrCypB Formulated with Freund’s Adjuvant Confers Protective Immunity Against S. globosa and Partial Cross-Protection Against S. schenckii Infections in Mice
Sporothrix globosa is the predominant cause of sporotrichosis in China, highlighting the need for effective vaccine strategies. Cyclophilins from pathogenic microorganisms have emerged as potential vaccine antigens. We previously generated a high-yield, high-purity recombinant truncated S. globosa cyclophilin B protein (SgtrCypB) retaining its functional domain. Here, BALB/c mice were immunized subcutaneously with SgtrCypB alone or formulated with Freund’s adjuvant to evaluate immunogenicity. Only the adjuvant-formulated vaccine induced a high antibody titer (1:51,200). Then, the infection-challenge experiments compared the SgtrCypB formulated with Freund’s adjuvant and PBS formulated with Freund’s adjuvant groups. Following challenge, SgtrCypB plus adjuvant reduced cutaneous lesion size (0.6 vs. 1.0 cm at week 1) without significantly affecting ulcer incidence. In systemic S. globosa infection, vaccination increased survival to 90% versus 40% in controls and reduced organ fungal burdens. Partial cross-protection was observed against S. schenckii, with 60% versus 20% survival and lower fungal burdens in the kidneys and lungs. Protection against C. albicans was minimal. These findings identify SgtrCypB as a promising protective antigen against S. globosa and S. schenckii and support further evaluation with clinically applicable adjuvants.
- 21 September 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (9) , 706
Open AccessSgtrCypB Formulated with Freund’s Adjuvant Confers Protective Immunity Against S. globosa and Partial Cross-Protection Against S. schenckii Infections in Mice
Sporothrix globosa is the predominant cause of sporotrichosis in China, highlighting the need for effective vaccine strategies. Cyclophilins from pathogenic microorganisms have emerged as potential vaccine antigens. We previously generated a high-yield, high-purity recombinant truncated S. globosa cyclophilin B protein (SgtrCypB) retaining its functional domain. Here, BALB/c mice were immunized subcutaneously with SgtrCypB alone or formulated with Freund’s adjuvant to evaluate immunogenicity. Only the adjuvant-formulated vaccine induced a high antibody titer (1:51,200). Then, the infection-challenge experiments compared the SgtrCypB formulated with Freund’s adjuvant and PBS formulated with Freund’s adjuvant groups. Following challenge, SgtrCypB plus adjuvant reduced cutaneous lesion size (0.6 vs. 1.0 cm at week 1) without significantly affecting ulcer incidence. In systemic S. globosa infection, vaccination increased survival to 90% versus 40% in controls and reduced organ fungal burdens. Partial cross-protection was observed against S. schenckii, with 60% versus 20% survival and lower fungal burdens in the kidneys and lungs. Protection against C. albicans was minimal. These findings identify SgtrCypB as a promising protective antigen against S. globosa and S. schenckii and support further evaluation with clinically applicable adjuvants.
- Open Access
- 29 December 2025
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
D-lactic acid inhibits Candida albicans associated with vulvovaginal candidiasis: in vitro and in vivo effects and underlying mechanisms
Candida albicans (C. albicans) is a major opportunistic fungal pathogen responsible for both invasive and superficial infections, including vulvovaginal ca
- 29 December 2025
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Open AccessD-lactic acid inhibits Candida albicans associated with vulvovaginal candidiasis: in vitro and in vivo effects and underlying mechanisms
Candida albicans (C. albicans) is a major opportunistic fungal pathogen responsible for both invasive and superficial infections, including vulvovaginal ca
- Open Access
- 9 January 2024
- Published by Oxford University Press (OUP) in Journal of Industrial Microbiology and Biotechnology
- Vol. 51
Optimized expression of Peptidyl-prolyl cis/transisomerase cyclophilinB with prokaryotic toxicity from Sporothrix globosa
Cyclophilin B (CypB), a significant member of immunophilins family with peptidyl-prolyl cis-trans isomerase (PPIase) activity, is crucial for the growth and metabolism of prokaryotes and eukaryotes. Sporothrix globosa (S. globosa), a principal pathogen in the Sporothrix complex, causes sporotrichosis. Transcriptomic analysis identified the cypB gene as highly expressed in S. globosa. Our previous study demonstrated that the recombinant Escherichia coli strain containing SgcypB gene failed to produce sufficient product when it was induced to express the protein, implying the potential toxicity of recombinant protein to the bacterial host. Bioinformatics analysis revealed that SgCypB contains transmembrane peptides within the 52 amino acid residues at the N-terminus and 21 amino acids near the C-terminus, and 18 amino acid residues within the cytoplasm. AlphaFold2 predicted a SgCypB 3D structure in which there is an independent PPIase domain consisting of a spherical extracellular part. Hence, we chose to express the extracellular domain to yield high-level recombinant protein with PPIase activity. Finally, we successfully produced high-yield, truncated recombinant CypB protein from S. globosa (SgtrCypB) that retained characteristic PPIase activity without host bacterium toxicity. This study presents an alternative expression strategy for proteins toxic to prokaryotes, such as SgCypB. The recombinant cyclophilin B protein of Sporothrix globosa was expressed successfully by retaining extracellular domain with peptidyl-prolyl cis-trans isomerase activity to avoid toxicity to the host bacterium.
- 9 January 2024
- Published by Oxford University Press (OUP) in Journal of Industrial Microbiology and Biotechnology
- Vol. 51
Open AccessOptimized expression of Peptidyl-prolyl cis/transisomerase cyclophilinB with prokaryotic toxicity from Sporothrix globosa
Cyclophilin B (CypB), a significant member of immunophilins family with peptidyl-prolyl cis-trans isomerase (PPIase) activity, is crucial for the growth and metabolism of prokaryotes and eukaryotes. Sporothrix globosa (S. globosa), a principal pathogen in the Sporothrix complex, causes sporotrichosis. Transcriptomic analysis identified the cypB gene as highly expressed in S. globosa. Our previous study demonstrated that the recombinant Escherichia coli strain containing SgcypB gene failed to produce sufficient product when it was induced to express the protein, implying the potential toxicity of recombinant protein to the bacterial host. Bioinformatics analysis revealed that SgCypB contains transmembrane peptides within the 52 amino acid residues at the N-terminus and 21 amino acids near the C-terminus, and 18 amino acid residues within the cytoplasm. AlphaFold2 predicted a SgCypB 3D structure in which there is an independent PPIase domain consisting of a spherical extracellular part. Hence, we chose to express the extracellular domain to yield high-level recombinant protein with PPIase activity. Finally, we successfully produced high-yield, truncated recombinant CypB protein from S. globosa (SgtrCypB) that retained characteristic PPIase activity without host bacterium toxicity. This study presents an alternative expression strategy for proteins toxic to prokaryotes, such as SgCypB. The recombinant cyclophilin B protein of Sporothrix globosa was expressed successfully by retaining extracellular domain with peptidyl-prolyl cis-trans isomerase activity to avoid toxicity to the host bacterium.
- Open Access
- 25 June 2021
- Published by Springer Nature in BMC Microbiology
- Vol. 21 (1) , 1-9
Chitin-rich heteroglycan from Sporothrix schenckii sensu stricto potentiates fungal clearance in a mouse model of sporotrichosis and promotes macrophages phagocytosis
Background: Fungal cell wall polysaccharides maintain the integrity of fungi and interact with host immune cells. The immunomodulation of fungal polysaccharides has been demonstrated in previous studies. However, the effect of chitin-rich heteroglycan extracted fromSporothrix schenckiisensu strictoon the immune response has not been investigated.Results: In this study, chitin-rich heteroglycan was extracted fromS. schenckiisensu stricto, and immunomodulation was investigated via histopathological analysis of skin lesions in a mouse model of sporotrichosis and evaluation of the phagocytic function and cytokine secretion of macrophages in vitro. The results showed that the skin lesions regressed and granulomatous inflammation was reduced in infected mice within 5 weeks. Moreover, heteroglycan promoted the fungal phagocytosis by macrophages and modulated the cytokine secretion. Heteroglycan upregulated TNF-α expression early at 24 h and IL-12 expression late at 72 h after incubation, which might result from moderate activation of macrophages and contribute to the subsequent adaptive immune response.Conclusions: Chitin-rich heteroglycan extracted fromS. schenckiisensu strictopotentiated fungal clearance in a mouse model of sporotrichosis. Moreover, chitin-rich heteroglycan promoted fungus phagocytosis by macrophages and modulated cytokines secretion. These results might indicate that chitin-rich heteroglycan could be considered as an immunomodulator used in the treatment of sporotrichosis.
- 25 June 2021
- Published by Springer Nature in BMC Microbiology
- Vol. 21 (1) , 1-9
Open AccessChitin-rich heteroglycan from Sporothrix schenckii sensu stricto potentiates fungal clearance in a mouse model of sporotrichosis and promotes macrophages phagocytosis
Background: Fungal cell wall polysaccharides maintain the integrity of fungi and interact with host immune cells. The immunomodulation of fungal polysaccharides has been demonstrated in previous studies. However, the effect of chitin-rich heteroglycan extracted fromSporothrix schenckiisensu strictoon the immune response has not been investigated.Results: In this study, chitin-rich heteroglycan was extracted fromS. schenckiisensu stricto, and immunomodulation was investigated via histopathological analysis of skin lesions in a mouse model of sporotrichosis and evaluation of the phagocytic function and cytokine secretion of macrophages in vitro. The results showed that the skin lesions regressed and granulomatous inflammation was reduced in infected mice within 5 weeks. Moreover, heteroglycan promoted the fungal phagocytosis by macrophages and modulated the cytokine secretion. Heteroglycan upregulated TNF-α expression early at 24 h and IL-12 expression late at 72 h after incubation, which might result from moderate activation of macrophages and contribute to the subsequent adaptive immune response.Conclusions: Chitin-rich heteroglycan extracted fromS. schenckiisensu strictopotentiated fungal clearance in a mouse model of sporotrichosis. Moreover, chitin-rich heteroglycan promoted fungus phagocytosis by macrophages and modulated cytokines secretion. These results might indicate that chitin-rich heteroglycan could be considered as an immunomodulator used in the treatment of sporotrichosis.
- 22 August 2018
- Published by Elsevier in Molecular and Biochemical Parasitology
- Vol. 226, 1-8
Antibodies against Schistosoma japonicum lactate dehydrogenase B enhance enzyme active
- 22 August 2018
- Published by Elsevier in Molecular and Biochemical Parasitology
- Vol. 226, 1-8
Antibodies against Schistosoma japonicum lactate dehydrogenase B enhance enzyme active
- 1 June 2018
- Published by Elsevier in International Immunopharmacology
- Vol. 59, 347-353
Clonorchis sinensis cyclophilin A immunization protected mice from CLP-induced sepsis
- 1 June 2018
- Published by Elsevier in International Immunopharmacology
- Vol. 59, 347-353
Clonorchis sinensis cyclophilin A immunization protected mice from CLP-induced sepsis
- 1 May 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 34, 263-270
Antifungal curcumin promotes chitin accumulation associated with decreased virulence of Sporothrix schenckii
- 1 May 2016
- Published by Elsevier in International Immunopharmacology
- Vol. 34, 263-270
Antifungal curcumin promotes chitin accumulation associated with decreased virulence of Sporothrix schenckii
- 16 March 2016
- Published by Elsevier in Journal of Surgical Research
- Vol. 203 (2) , 476-482
Survival advantage depends on cecal volume rather than cecal length in a mouse model of cecal ligation and puncture
- 16 March 2016
- Published by Elsevier in Journal of Surgical Research
- Vol. 203 (2) , 476-482
Survival advantage depends on cecal volume rather than cecal length in a mouse model of cecal ligation and puncture
- 15 January 2016
- Published by Springer Nature in Parasitology Research
- Vol. 115 (4) , 1595-1603
Antibodies against Clonorchis sinensis LDH could cross-react with LDHB localizing on the plasma membrane of human hepatocarcinoma cell SMMC-7721 and induce apoptosis
Lactate dehydrogenase (LDH) is a terminal enzyme in anaerobic glycolytic pathway. It widely exists in various organisms and is in charge of converting the glycolysis product pyruvic acid to lactic acid. Most parasites, including Clonorchis sinensis, predominantly depend on glycolysis to provide energy. Bioinformatic analysis predicts that the LDHs from many species have more than one transmembrane region, suggesting that it may be a membrane protein. C. sinensis LDH (CsLDH) has been confirmed as a transmembrane protein mainly located in the tegument. The antibodies against CsLDH can inhibit the worm’s energy metabolism, kill the worm, and may have the same effects on human cancer cells. In this study, we cloned and characterized human LDHA (HsLDHA), HsLDHB, and CsLDH. Semi-quantitative real-time RCP showed that HsLDHB only existed in hepatocarcinoma cell SMMC-7721. Confocal microscopy and Western blot experiments revealed that HsLDHB was localized in the plasma membrane of SMMC-7721 cells, and the antibodies against CsLDH could cross-react with it. This cross-reaction could inhibit the enzymatic activity of HsLDHB. The cancer cells co-cultured with anti-CsLDH sera showed a significant decrease in cell proliferation rate and increases in caspase 9 and reactive oxygen species (ROS) levels. Therefore, anti-CsLDH antibodies can induce the apoptosis of cancer cells SMMC-7721 and may serve as a new tool to inhibit tumor.
- 15 January 2016
- Published by Springer Nature in Parasitology Research
- Vol. 115 (4) , 1595-1603
Antibodies against Clonorchis sinensis LDH could cross-react with LDHB localizing on the plasma membrane of human hepatocarcinoma cell SMMC-7721 and induce apoptosis
Lactate dehydrogenase (LDH) is a terminal enzyme in anaerobic glycolytic pathway. It widely exists in various organisms and is in charge of converting the glycolysis product pyruvic acid to lactic acid. Most parasites, including Clonorchis sinensis, predominantly depend on glycolysis to provide energy. Bioinformatic analysis predicts that the LDHs from many species have more than one transmembrane region, suggesting that it may be a membrane protein. C. sinensis LDH (CsLDH) has been confirmed as a transmembrane protein mainly located in the tegument. The antibodies against CsLDH can inhibit the worm’s energy metabolism, kill the worm, and may have the same effects on human cancer cells. In this study, we cloned and characterized human LDHA (HsLDHA), HsLDHB, and CsLDH. Semi-quantitative real-time RCP showed that HsLDHB only existed in hepatocarcinoma cell SMMC-7721. Confocal microscopy and Western blot experiments revealed that HsLDHB was localized in the plasma membrane of SMMC-7721 cells, and the antibodies against CsLDH could cross-react with it. This cross-reaction could inhibit the enzymatic activity of HsLDHB. The cancer cells co-cultured with anti-CsLDH sera showed a significant decrease in cell proliferation rate and increases in caspase 9 and reactive oxygen species (ROS) levels. Therefore, anti-CsLDH antibodies can induce the apoptosis of cancer cells SMMC-7721 and may serve as a new tool to inhibit tumor.
- 14 December 2015
- Published by Springer Nature in Parasitology Research
- Vol. 115 (3) , 903-912
Should we abandon quinine plus antibiotic for treating uncomplicated falciparum malaria? A systematic review and meta-analysis of randomized controlled trials
In this study, we compared the efficacies and adverse effects of quinine plus antibiotics and other anti-malaria drugs on treating uncomplicated falciparum malaria. By systematically searching the major databases PubMed, Embase, and the Cochrane Library, 14 randomized controlled trials (RCTs) including 1996 cases were identified. Then, we performed a systematic review and cumulative meta-analysis on these data. The primary outcome of these treatments was parasite failure at day 28. There was no significant difference between quinine plus antibiotic therapy (QACT) and artemisinin-based therapies (odds ratio (OR) 0.69, 95 % confidence interval (CI) 0.28 to 1.71) or non-artemisinin-based therapies except quinine monotherapy and chloroquine monotherapy (OR 0.56, 95 % CI 0.18 to 1.74). The secondary outcome was the adverse effects within 28 days, including nausea, dizziness, vomiting, diarrhea, abdominal pain, headache, and tinnitus. QACT significantly increased the risk of tinnitus compared with artemisinin-based therapies (OR 111.65, 95 % CI 12.63 to 986.87) and non-artemisinin-based therapies (OR 48.16, 95 % CI 16.23 to 142.92). Vomiting was more frequently reported in QACT compared with non-artemisinin-based therapies (OR 2.02, 95 % CI 1.14 to 3.56). This meta-analysis suggests that almost all regimens have equivalent treatment effect at the 28th day. However, the patients with QACT had a higher chance to suffer from vomiting and tinnitus. Therefore, QACT does not have significant advantage on treating uncomplicated falciparum malaria.
- 14 December 2015
- Published by Springer Nature in Parasitology Research
- Vol. 115 (3) , 903-912
Should we abandon quinine plus antibiotic for treating uncomplicated falciparum malaria? A systematic review and meta-analysis of randomized controlled trials
In this study, we compared the efficacies and adverse effects of quinine plus antibiotics and other anti-malaria drugs on treating uncomplicated falciparum malaria. By systematically searching the major databases PubMed, Embase, and the Cochrane Library, 14 randomized controlled trials (RCTs) including 1996 cases were identified. Then, we performed a systematic review and cumulative meta-analysis on these data. The primary outcome of these treatments was parasite failure at day 28. There was no significant difference between quinine plus antibiotic therapy (QACT) and artemisinin-based therapies (odds ratio (OR) 0.69, 95 % confidence interval (CI) 0.28 to 1.71) or non-artemisinin-based therapies except quinine monotherapy and chloroquine monotherapy (OR 0.56, 95 % CI 0.18 to 1.74). The secondary outcome was the adverse effects within 28 days, including nausea, dizziness, vomiting, diarrhea, abdominal pain, headache, and tinnitus. QACT significantly increased the risk of tinnitus compared with artemisinin-based therapies (OR 111.65, 95 % CI 12.63 to 986.87) and non-artemisinin-based therapies (OR 48.16, 95 % CI 16.23 to 142.92). Vomiting was more frequently reported in QACT compared with non-artemisinin-based therapies (OR 2.02, 95 % CI 1.14 to 3.56). This meta-analysis suggests that almost all regimens have equivalent treatment effect at the 28th day. However, the patients with QACT had a higher chance to suffer from vomiting and tinnitus. Therefore, QACT does not have significant advantage on treating uncomplicated falciparum malaria.